Skip to main content
. 2021 Feb 27;89(6):1088–1098. doi: 10.1002/ana.26049

FIGURE 2.

FIGURE 2

Clinical profiles of patients receiving eculizumab during PREVENT and the OLE who experienced adjudicated relapses. ARR = annualized relapse rate; EDSS = Expanded Disability Status Scale; IST = immunosuppressive therapy; NMOSD = neuromyelitis optics spectrum disorder; OLE = open‐label extension.